| Period Ending: | 2025 12-31 |
2024 12-31 |
2023 12-31 |
2022 12-31 |
2021 12-31 |
2020 12-31 |
|---|---|---|---|---|---|---|
| Total |
1234
|
|||||
| License |
1234
|
|||||
| License (%) |
1234
|
|||||
| R&D Services |
1234
|
|||||
| R&D Services (%) |
1234
|
|||||
| Development Services |
1234
|
|||||
| Development Services (%) |
1234
|
|||||
| License And Development Services |
1234
|
|||||
| License And Development Services (%) |
1234
|
|||||
| Other Collaboration Revenue |
1234
|
|||||
| Other Collaboration Revenue (%) |
1234
|
|||||
| License and Development Services Revenue |
1234
|
|||||
| License and Development Services Revenue (%) |
1234
|
|||||
| Development Services for all Gilead Programs |
1234
|
|||||
| Development Services for all Gilead Programs (%) |
1234
|
|||||
| Gilead Access Rights |
1234
|
|||||
| Gilead Access Rights (%) |
1234
|
|||||
| Gilead License to Domvanalimab |
1234
|
|||||
| Gilead License to Domvanalimab (%) |
1234
|
|||||
| Taiho Access Rights |
1234
|
|||||
| Taiho Access Rights (%) |
1234
|
|||||
| Taiho License to Domvanalimab |
1234
|
|||||
| Taiho License to Domvanalimab (%) |
1234
|
|||||
| Gilead License To Zimberelimab |
1234
|
|||||
| Gilead License To Zimberelimab (%) |
1234
|
|||||
| Taiho Collaboration Agreement |
1234
|
|||||
| Taiho Collaboration Agreement (%) |
1234
|
|||||
